<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-85736" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ropinirole</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rewane</surname>
            <given-names>Ayesan</given-names>
          </name>
          <aff>Rush University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayesan Rewane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-85736.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. As a dopamine agonist, it acts on G-protein-coupled inhibitory neurons, inhibiting adenylyl cyclase and calcium&#x000a0;channels while activating potassium channels. This mechanism maximizes the "on" time and minimizes the "off" time associated with disease progression, making ropinirole an attractive option for&#x000a0;managing early and advanced-stage PD. Beyond its primary indications, ropinirole has also proved effective in addressing sleep disturbances and nocturnal symptoms linked to PD. This activity explores the applications of ropinirole and discusses its indications, contraindications, mechanism of action, adverse events, and essential considerations&#x000a0;when using it as a therapy component.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the approved indications for ropinirole therapy.</p></list-item><list-item><p>Recognize the possible adverse effects of ropinirole.</p></list-item><list-item><p>Screen patients for ropinirole therapy based on its contraindications.</p></list-item><list-item><p>Implement coordinated&#x000a0;care between members of the interprofessional team when using ropinirole therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=85736&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=85736">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-85736.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Dopamine agonists are drugs used to treat various central nervous system disorders. Ergoline (eg, bromocriptine) and non-ergoline dopamine agonists (eg, ropinirole, pramipexole) are useful&#x000a0;in treating Parkinson disease (PD). Ropinirole is a US Food and Drug Administration-approved medication indicated for treating restless legs syndrome (RLS) and PD. The drug acts by selectively binding to D2 receptors.&#x000a0;Ropinirole treats both early and advanced-stage Parkinson disease and can&#x000a0;maximize the "on" time and minimize the "off" time of the disease.&#x000a0;Ropinirole is also helpful in managing sleep disturbances and nocturnal&#x000a0;symptoms&#x000a0;associated with Parkinson disease.<xref ref-type="bibr" rid="article-85736.r1">[1]</xref><xref ref-type="bibr" rid="article-85736.r2">[2]</xref><xref ref-type="bibr" rid="article-85736.r3">[3]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Parkinson Disease&#x000a0;</bold>
</p>
        <p>Parkinson disease (PD) is a condition characterized by the loss of dopamine receptors in the substantia nigra pars compacta leading to cognitive and motor decline. Rigidity, tremors, and bradykinesia are&#x000a0;common&#x000a0;features of this disease.<xref ref-type="bibr" rid="article-85736.r4">[4]</xref> There are periods when these patients demonstrate good motor function, referred to as 'on' time, and&#x000a0;periods of&#x000a0;severe motor decline, referred to as 'off' time. Ropinirole is equally effective in treating PD as monotherapy or in combination with other medications like L-dopa.<xref ref-type="bibr" rid="article-85736.r5">[5]</xref>&#x000a0;According to the American Academy of Neurology guidelines, clinicians&#x000a0;should prescribe the lowest dose of&#x000a0;dopamine agonist like ropinirole for motor symptoms in early PD.<xref ref-type="bibr" rid="article-85736.r6">[6]</xref></p>
        <p>
<bold>Restless Leg Syndrome&#x000a0;</bold>
</p>
        <p>Restless leg syndrome (RLS), also known as Willis-Ekbom disease, is the uncontrollable urge to move the legs&#x000a0;to resolve a sensation commonly described as burning, painful, or tingling.<xref ref-type="bibr" rid="article-85736.r7">[7]</xref> Ropinirole also treats moderate to severe RLS; relief can occur within&#x000a0;2 days of initiating treatment.<xref ref-type="bibr" rid="article-85736.r8">[8]</xref>&#x000a0;The American Academy of Sleep Medicine (AASM) endorses using dopamine agonists like ropinirole to manage moderate-to-severe RLS.<xref ref-type="bibr" rid="article-85736.r9">[9]</xref></p>
      </sec>
      <sec id="article-85736.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ropinirole has a high affinity for post-synaptic dopamine receptors in the central and peripheral nervous systems. The dopamine receptors (D2) are G-protein-coupled inhibitory neurons located&#x000a0;primarily in the striatonigral, mesolimbic, and tuberoinfundibular systems. They inhibit adenylyl cyclase and calcium&#x000a0;channels and activate potassium channels.<xref ref-type="bibr" rid="article-85736.r10">[10]</xref><xref ref-type="bibr" rid="article-85736.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Orally administered ropinirole is rapidly absorbed and reaches peak plasma concentration in 1 to 2 hours. About 50% of the drug is metabolized on first-pass, and the absolute bioavailability ranges from 45% to 55%.&#x000a0;The drug reaches steady-state concentrations within&#x000a0;2 days of initiating ropinirole. A high-fat diet may delay absorption, prolong the Tmax by 2.5 hours, and decrease the Cmax by 25%; ropinirole is better absorbed during fasting.</p>
        <p><bold>Distribution:</bold>&#x000a0;Ropinirole has a volume of distribution of 7.5 L/kg, and 40% of the drug is bound to plasma proteins.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Most ropinirole is metabolized in the liver by <italic toggle="yes">N</italic>-despropylation and hydroxylation to form inactive metabolites. Cytochrome P450 1A2 is the primary enzyme involved in the metabolism of ropinirole.<xref ref-type="bibr" rid="article-85736.r2">[2]</xref><xref ref-type="bibr" rid="article-85736.r12">[12]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;The elimination half-life of the ropinirole immediate-release tablet is approximately 6 hours, and less than 10% of the orally administered drug is excreted unchanged in urine.</p>
      </sec>
      <sec id="article-85736.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Two oral formulations are available as immediate-release tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg) and prolonged/extended-release tablets (2 mg, 4 mg, 6 mg, 8 mg, and 12 mg). The immediate-release form is administered&#x000a0;3 times daily, while the extended-release is once-daily.<xref ref-type="bibr" rid="article-85736.r1">[1]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The therapeutic level for this drug is between 0.4 and 6&#x000a0;ng/mL; its use requires caution in older patients (older than 65) and women on hormonal replacement therapy (HRT) because of the slower clearance of the medication in these groups.<xref ref-type="bibr" rid="article-85736.r2">[2]</xref><xref ref-type="bibr" rid="article-85736.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>In PD treatment, a dose&#x000a0;of 6&#x000a0;to 24 mg of the extended-release formulation is usually well-tolerated, and the clinician can individualize&#x000a0;dosing from patient to patient.<xref ref-type="bibr" rid="article-85736.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>
<bold>Parkinson Disease&#x000a0;</bold>
</p>
        <p><bold>Immediate-Release Tablets:</bold>&#x000a0;The dose is titrated gradually every week in the following table.&#x000a0;If therapy with ropinirole is significantly interrupted, re-titration of the dose may be necessary.</p>
        <table-wrap id="article-85736.table0" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 36px; height: 13px;" rowspan="1" colspan="1">Week</td>
                <td style="width: 188px; height: 13px;" rowspan="1" colspan="1">Dosage</td>
                <td style="width: 128.562px; height: 13px;" rowspan="1" colspan="1">Total Daily Dose</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 36px; height: 13px;" rowspan="1" colspan="1">1</td>
                <td style="width: 188px; height: 13px;" rowspan="1" colspan="1">0.25 mg&#x000a0;3 times daily</td>
                <td style="width: 128.562px; height: 13px;" rowspan="1" colspan="1">0.75 mg</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 36px; height: 13px;" rowspan="1" colspan="1">2</td>
                <td style="width: 188px; height: 13px;" rowspan="1" colspan="1">0.5&#x000a0;mg&#x000a0;3 times daily</td>
                <td style="width: 128.562px; height: 13px;" rowspan="1" colspan="1">1.5 mg</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 36px; height: 13px;" rowspan="1" colspan="1">3</td>
                <td style="width: 188px; height: 13px;" rowspan="1" colspan="1">0.75&#x000a0;mg&#x000a0;3 times daily</td>
                <td style="width: 128.562px; height: 13px;" rowspan="1" colspan="1">2.25 mg</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 36px; height: 13px;" rowspan="1" colspan="1">4</td>
                <td style="width: 188px; height: 13px;" rowspan="1" colspan="1">1&#x000a0;mg&#x000a0;3 times daily</td>
                <td style="width: 128.562px; height: 13px;" rowspan="1" colspan="1">3 mg</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Ropinirole tablets should be discontinued gradually and tapered over&#x000a0;7 days in patients with PD according to the following method. First, the administration dose should be reduced from&#x000a0;3 times daily to twice daily for the first&#x000a0;4 days. For the 3 following days, dosing should be reduced to once-daily before cessation of ropinirole.</p>
        <p><bold>Extended-Release Tablets:&#x000a0;</bold>The initial dose is 2 mg, administered once-daily for&#x000a0;2 weeks. Then, the dose may be increased by 2 mg weekly or at longer intervals based on the patient&#x02019;s response. The maximum dose is 24 mg administered daily.</p>
        <p>
<bold>Restless Legs Syndrome&#x000a0;</bold>
</p>
        <p>The recommended initial adult dose for RLS is 0.25 mg once-daily, about&#x000a0;1 to&#x000a0;3 hours before bedtime. A dose of 2 mg or less would suffice, and starting on a low dose is a good practice. In patients with RLS, ropinirole is usually started at a dose of 0.25 mg per day, incrementing 0.25 mg every&#x000a0;2 to&#x000a0;3 days until the reduction of symptoms.<xref ref-type="bibr" rid="article-85736.r15">[15]</xref>&#x000a0;After&#x000a0;2 days, the dose can be increased to 0.5 mg once-daily (days 3 to 7) and 1 mg once-daily at the end of the first week of dosing to achieve optimal efficacy.</p>
        <p>Dose titration after 1 week is as follows: week 2: 1 mg daily; week 3: 1.5 mg daily; week 4: 2.5 mg daily; week 5: 3 mg daily; week 6: 3.5 mg daily; week 7: 4 mg daily. This titration should be based on individual patient tolerability and therapeutic response to a maximum daily dose of 4 mg.&#x000a0;When discontinuing ropinirole treatment in patients with RLS, a gradual decrease of the daily dose is recommended.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Pharmacokinetic studies of ropinirole have not been conducted in patients with hepatic impairment.&#x000a0;Caution is advised as ropinirole is metabolized in the liver.<xref ref-type="bibr" rid="article-85736.r16">[16]</xref></p>
        <p><bold>Renal impairment:&#x000a0;</bold>Dose adjustments are not required in patients with moderate renal impairment (CrCl of 30 to 50 mL/min). Patients with RLS and end-stage renal disease and on hemodialysis should be started on 0.25 mg once-daily. Further dose increments are based on the need for efficacy and tolerability. The recommended maximum daily dose is 3 mg in patients receiving regular dialysis. Supplemental doses after dialysis are not needed.</p>
        <p><bold>Pregnancy considerations:</bold> If a patient using ropinirole intends to get pregnant or get pregnant, they should report to their clinician. Ropinirole is a pregnancy category C medicine. In addition, animal studies have reported teratogenic effects, so patients should be advised of this potential risk.</p>
        <p><bold>Breastfeeding considerations:</bold> There is a lack of information on&#x000a0;ropinirole&#x000a0;use during breastfeeding. Since ropinirole suppresses serum prolactin, it can interfere with lactation. Alternative medicine is preferred while breastfeeding newborn or preterm infants.<xref ref-type="bibr" rid="article-85736.r17">[17]</xref></p>
        <p><bold>Pediatric patients: </bold>The safety and efficacy of ropinirole have not been established in this population.</p>
        <p><bold>Older patients: </bold>Increased adverse drug reactions such as hallucination, nausea, and vomiting&#x000a0;have been&#x000a0;reported. Dosage should be titrated slowly&#x000a0;based&#x000a0;on clinical response.<xref ref-type="bibr" rid="article-85736.r18">[18]</xref></p>
      </sec>
      <sec id="article-85736.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Rare cases of hypersensitivity reactions, falling asleep during activities of daily living, somnolence (especially if concomitantly using CNS depressants), hallucinations, compulsive behaviors, augmentation, early morning rebound RLS, fibrotic complications, and retinal degeneration are also reported in clinical trials and postmarketing experience.</p>
        <p><bold>Peripheral edema:&#x000a0;</bold>Peripheral edema has been reported in&#x000a0;up to one-third of the patients on the extended-release form.<xref ref-type="bibr" rid="article-85736.r19">[19]</xref></p>
        <p><bold>Anterocollis:&#x000a0;</bold>The definition of this condition is the head positioned in flexion, resembling a "drooping head," a rare side effect reported in a patient taking ropinirole. Discontinuation of the medication progressively reversed the symptoms within 4 months.<xref ref-type="bibr" rid="article-85736.r20">[20]</xref></p>
        <p><bold>Pisa syndrome:&#x000a0;</bold>Cases of ropinirole-induced Pisa syndrome, referred to as "pleurothotonus," have been recorded.&#x000a0;The condition is characterized by an abnormal lateral flexion of the trunk to the right or left. This condition occurred after a year on the medication and resolved 3 months after cessation of treatment. However, some reports maintain that Pisa syndrome is irreversible despite discontinuing this medication.<xref ref-type="bibr" rid="article-85736.r21">[21]</xref><xref ref-type="bibr" rid="article-85736.r22">[22]</xref></p>
        <p><bold>Reversible dyskinesias:&#x000a0;</bold>Another movement disorder observed with ropinirole is severe reversible dyskinesias, which is very rare. This dose-dependent choreoform dyskinesia occurred in ropinirole monotherapy up to a dose of 15 mg daily but was also observed at a dose of 6 mg daily.<xref ref-type="bibr" rid="article-85736.r23">[23]</xref></p>
        <p><bold>Dermal eruptions:&#x000a0;</bold>Similar to other&#x000a0;D2 agonists, ropinirole rarely caused fixed dermal eruptions. This adverse effect is thought to be due to the inactivation of T cells.<xref ref-type="bibr" rid="article-85736.r24">[24]</xref></p>
        <p><bold>Dopamine-agonist withdrawal syndroms:&#x000a0;</bold>Withdrawal-emergent hyperpyrexia and confusion are reported in patients where ropinirole treatment is abruptly stopped or the dose is rapidly tapered down.&#x000a0;This condition resembles neuroleptic malignant syndrome without specific etiology. Withdrawal symptoms include insomnia, anxiety, apathy, depression, sweating, fatigue, and pain, which do not respond to treatment with levodopa. Recommendations include informing patients about the potential for withdrawal symptoms and monitoring symptoms during taper down and after treatment cessation.<xref ref-type="bibr" rid="article-85736.r25">[25]</xref>&#x000a0;</p>
        <p><bold>Impulse control disorders:&#x000a0;</bold>Case reports of increased sexual drive, gambling, and binge eating have been reported. The&#x000a0;mechanism of action is thought to be the stimulation of dopamine D3 receptors by dopamine agonists.&#x000a0;Patients&#x000a0;have reported&#x000a0;an inability to control their urges. Patients may not convey problems to clinicians&#x000a0;due to embarrassment. In&#x000a0;severe&#x000a0;cases, clinicians should consider decreasing the dose of ropinirole; severe cases may require cessation of therapy.<xref ref-type="bibr" rid="article-85736.r26">[26]</xref><xref ref-type="bibr" rid="article-85736.r27">[27]</xref><xref ref-type="bibr" rid="article-85736.r28">[28]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>CYP1A2 enzyme is induced by omeprazole and smoking and can decrease the plasma concentration of ropinirole. CYP1A2 is inhibited by fluoroquinolones (eg, ciprofloxacin and norfloxacin), fluvoxamine, and mexiletine. The administration of these drugs may increase the plasma level of this drug.<xref ref-type="bibr" rid="article-85736.r12">[12]</xref></p>
        <p>Hormone replacement therapy (HRT, high dose estrogens) reduces the clearance of ropinirole; dose adjustment may be required when starting or stopping HRT.</p>
        <p>Dopamine antagonists&#x000a0;phenothiazines, thioxanthenes, butyrophenones, and metoclopramide can reduce the&#x000a0;efficacy of ropinirole. Concurrent administration of ropinirole and metoclopramide should be avoided.<xref ref-type="bibr" rid="article-85736.r29">[29]</xref></p>
        <p>As with most dopamine agonists, ropinirole's most frequently reported adverse effects&#x000a0;include nausea, vomiting, dyspepsia, abdominal pain, hallucinations, drowsiness, dizziness, leg edema, viral infection, syncope, orthostatic hypotension, and asthenic condition (ie, weakness, fatigue, and malaise).<xref ref-type="bibr" rid="article-85736.r11">[11]</xref><xref ref-type="bibr" rid="article-85736.r30">[30]</xref><xref ref-type="bibr" rid="article-85736.r31">[31]</xref></p>
      </sec>
      <sec id="article-85736.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Clinicians should avoid using ropinirole in&#x000a0;patients who&#x000a0;abuse alcohol and patients with liver failure.<xref ref-type="bibr" rid="article-85736.r16">[16]</xref>&#x000a0;Ropinirole is contraindicated in patients who experience hypersensitivity reactions and anaphylaxis, including rash, pruritus, fixed drug eruptions, urticaria,&#x000a0;or angioedema to ropinirole or excipients.<xref ref-type="bibr" rid="article-85736.r24">[24]</xref></p>
      </sec>
      <sec id="article-85736.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients initiating ropinirole therapy or escalating doses of ropinirole should be monitored for signs and symptoms of orthostatic hypotension.&#x000a0;Monitoring of UPDRS (Unified Parkinson disease rating scale) is&#x000a0;suggested&#x000a0;for monitoring the response to therapy.<xref ref-type="bibr" rid="article-85736.r6">[6]</xref>&#x000a0;Patients should be informed about the potential for withdrawal symptoms with ropinirole and monitor those signs and symptoms during and after discontinuation of ropinirole.<xref ref-type="bibr" rid="article-85736.r25">[25]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-85736.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Ropinirole can cause death&#x000a0;when taken with alcohol,&#x000a0;and persons who excessively consume alcohol should not use the drug. A lethal level up to&#x000a0;6 times the therapeutic dose correlates with death.<xref ref-type="bibr" rid="article-85736.r13">[13]</xref>&#x000a0;</p>
        <p>Patients with liver insufficiency require close monitoring; a case report of liver toxicity exists. The medication is metabolized&#x000a0;primarily in the liver, and the toxicity may be due to an immune reaction or a possible toxic metabolite.<xref ref-type="bibr" rid="article-85736.r1">[1]</xref></p>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Of these patients who used doses&#x000a0;exceeding 24 mg per day, commonly reported adverse reactions were related to its dopaminergic activity, ie, nausea, dizziness, hyperhidrosis, visual hallucinations, claustrophobia, palpitations, chorea, asthenia, and nightmares. Additional symptoms reported in overdose patients included vomiting, agitation, chest pain, increased coughing, fatigue,&#x000a0;orthostatic hypotension, syncope, dyskinesia, somnolence, and a confusional state. A recent study describes shock and arrhythmias as the probable&#x000a0;reason for mortality associated with ropinirole overdose.<xref ref-type="bibr" rid="article-85736.r32">[32]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There have been reports of patients who intentionally or&#x000a0;accidentally took more than the maximum recommended daily dose of ropinirole in clinical trials. General supportive measures are recommended, and vitals should be maintained when necessary. In clinical trials, the most significant overdose reported with ropinirole was 62 mg daily for&#x000a0;7 days (total dose 435 mg).</p>
      </sec>
      <sec id="article-85736.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients and caregivers should receive education about ropinirole, including its indications, adverse effects, signs of toxicity, and drug withdrawal. Compliance with medication can be extremely challenging, especially in PD, and the once-daily prolonged release of ropinirole greatly improves medication compliance. Additionally, the severity of motor symptoms, such as tremors and rigidity, may also be an important factor to consider to improve the compliance and management of these patients.<xref ref-type="bibr" rid="article-85736.r1">[1]</xref><xref ref-type="bibr" rid="article-85736.r11">[11]</xref><xref ref-type="bibr" rid="article-85736.r33">[33]</xref> This is where an interprofessional team approach and consultation with a neurologist are most beneficial.</p>
        <p>Chronic RLS can be very challenging because of the sleep disruption for patients and family members. Ropinirole has demonstrated improved sleep quality, life, and mood in patients with RLS.<xref ref-type="bibr" rid="article-85736.r15">[15]</xref> However, clinicians should try alternative treatments before using dopamine agonists like ropinirole. If ropinirole therapy is initiated, it should be started at a very low dose. This dosing approach is recommended because chronic use of dopamine agonists causes &#x02018;augmentation,&#x0201d; which worsens symptoms and is often difficult to treat.<xref ref-type="bibr" rid="article-85736.r34">[34]</xref>&#x000a0;Sleep medicine specialist consultation may be necessary for refractory RLS cases.</p>
        <p>When prescribing ropinirole, the prescriber should consult the pharmacist, verify&#x000a0;the appropriateness of therapy and the optimal starting dose, and check for potential drug-drug interactions. Nursing staff can monitor patient progress with the patient or caregivers, assess compliance, answer questions, and monitor for adverse events, reporting anything of concern to the clinician with recommendations for treatment modification. Emergency medicine teams, critical care physicians, and medical toxicologists play a crucial role in the overdose of ropinirole. A psychiatrist should be consulted once the patient is stable if the overdose is intentional.</p>
      </sec>
      <sec id="article-85736.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=85736&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=85736">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/85736/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=85736">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-85736.s11">
        <title>References</title>
        <ref id="article-85736.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stocchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Radicati</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Torti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug safety evaluation of ropinirole prolonged release.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>383</fpage>
            <page-range>383-9</page-range>
            <pub-id pub-id-type="pmid">24490799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaye</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of ropinirole.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-54</page-range>
            <pub-id pub-id-type="pmid">11069211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muth</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Restless Legs Syndrome.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Feb</month>
            <day>21</day>
            <volume>317</volume>
            <issue>7</issue>
            <fpage>780</fpage>
            <pub-id pub-id-type="pmid">28241358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Parkinson Disease.</article-title>
            <source>Neurol Clin</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>955</fpage>
            <page-range>955-965</page-range>
            <pub-id pub-id-type="pmid">27720003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pahwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole therapy for Parkinson's disease.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>581</fpage>
            <page-range>581-8</page-range>
            <pub-id pub-id-type="pmid">15853577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>de Bie</surname>
                <given-names>RMA</given-names>
              </name>
              <name>
                <surname>Roze</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miyasaki</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Espay</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Martello</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gurwell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fitts</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cothros</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rafferty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagerbrant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Silsbee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <collab>Guideline Subcommittee of the AAN</collab>
            </person-group>
            <article-title>Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.</article-title>
            <source>Neurology</source>
            <year>2021</year>
            <month>Nov</month>
            <day>16</day>
            <volume>97</volume>
            <issue>20</issue>
            <fpage>942</fpage>
            <page-range>942-957</page-range>
            <pub-id pub-id-type="pmid">34782410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trenkwalder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>H&#x000f6;gl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schormair</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comorbidities, treatment, and pathophysiology in restless legs syndrome.</article-title>
            <source>Lancet Neurol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>994</fpage>
            <page-range>994-1005</page-range>
            <pub-id pub-id-type="pmid">30244828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chitnis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole treatment for restless legs syndrome.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2008</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-64</page-range>
            <pub-id pub-id-type="pmid">18484922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aurora</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Kristo</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bista</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rowley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zak</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lamm</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>RS</given-names>
              </name>
              <collab>American Academy of Sleep Medicine</collab>
            </person-group>
            <article-title>The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>Sleep</source>
            <year>2012</year>
            <month>Aug</month>
            <day>01</day>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1039</fpage>
            <page-range>1039-62</page-range>
            <pub-id pub-id-type="pmid">22851801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>The role of D2-autoreceptors in regulating dopamine neuron activity and transmission.</article-title>
            <source>Neuroscience</source>
            <year>2014</year>
            <month>Dec</month>
            <day>12</day>
            <volume>282</volume>
            <fpage>13</fpage>
            <page-range>13-22</page-range>
            <pub-id pub-id-type="pmid">24463000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nashatizadeh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Pahwa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A review of ropinirole prolonged release in Parkinson's disease.</article-title>
            <source>Clin Interv Aging</source>
            <year>2009</year>
            <volume>4</volume>
            <fpage>179</fpage>
            <page-range>179-86</page-range>
            <pub-id pub-id-type="pmid">19503779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shill</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Stacy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on ropinirole in the treatment of Parkinson's disease.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2009</year>
            <volume>5</volume>
            <fpage>33</fpage>
            <page-range>33-6</page-range>
            <pub-id pub-id-type="pmid">19557097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duband</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bidat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gaillard</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rochet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Camdessanche</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>P&#x000e9;oc'h</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A fatal intoxication case involving ropinirole.</article-title>
            <source>J Forensic Leg Med</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>422</fpage>
            <page-range>422-5</page-range>
            <pub-id pub-id-type="pmid">22920767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole prolonged release: in advanced Parkinson's disease.</article-title>
            <source>CNS Drugs</source>
            <year>2009</year>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-90</page-range>
            <pub-id pub-id-type="pmid">19062777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kushida</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole for the treatment of restless legs syndrome.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>407</fpage>
            <page-range>407-19</page-range>
            <pub-id pub-id-type="pmid">19412490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Ropinirole</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">31643503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Ropinirole</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greten</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Funogea</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Wegner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Junius-Walker</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gerbel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Klietz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-60</page-range>
            <pub-id pub-id-type="pmid">33263172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Csoti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jost</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Reichmann</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Parkinson's disease between internal medicine and neurology.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-17</page-range>
            <pub-id pub-id-type="pmid">26298728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ameghino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cammarota</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Merello</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole-Induced Anterocollis in Parkinson's Disease.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-92</page-range>
            <pub-id pub-id-type="pmid">30713901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>St&#x000e4;dler</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole-induced Pisa syndrome in Parkinson disease.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2014</year>
            <season>Mar-Apr</season>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>58</fpage>
            <page-range>58-9</page-range>
            <pub-id pub-id-type="pmid">24614668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellene</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saenz-Farret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Micheli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recurrent and Alternating Pisa Syndrome.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>252</fpage>
            <page-range>252-4</page-range>
            <pub-id pub-id-type="pmid">26536023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stamelou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mencacci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schapira</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease.</article-title>
            <source>Mov Disord</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>1159</fpage>
            <page-range>1159-60</page-range>
            <pub-id pub-id-type="pmid">23386566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasaki-Saito</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohmori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Omoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haruyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshioka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Multiple fixed drug eruption caused by ropinirole in a patient with Parkinson's disease.</article-title>
            <source>Allergol Int</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-222</page-range>
            <pub-id pub-id-type="pmid">26790807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nirenberg</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Dopamine agonist withdrawal syndrome: implications for patient care.</article-title>
            <source>Drugs Aging</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>8</issue>
            <fpage>587</fpage>
            <page-range>587-92</page-range>
            <pub-id pub-id-type="pmid">23686524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seeman</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.</article-title>
            <source>Synapse</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">25645960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Driver-Dunckley</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Hentz</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Evidente</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Caviness</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Parish</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krahn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2007</year>
            <season>Sep-Oct</season>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>249</fpage>
            <page-range>249-55</page-range>
            <pub-id pub-id-type="pmid">17909302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Contin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopane</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sambati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Massis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guarino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sermi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Persichella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Calandra-Buonaura</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.</article-title>
            <source>Neurol Sci</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>565</fpage>
            <page-range>565-572</page-range>
            <pub-id pub-id-type="pmid">36350455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeMaagd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.</article-title>
            <source>P T</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>9</issue>
            <fpage>590</fpage>
            <page-range>590-600</page-range>
            <pub-id pub-id-type="pmid">26417179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titlic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tonkic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jukic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lusic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dikanovic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Side effects of ropinirole in patients with idiopathic Parkinson's disease.</article-title>
            <source>Bratisl Lek Listy</source>
            <year>2008</year>
            <volume>109</volume>
            <issue>6</issue>
            <fpage>273</fpage>
            <page-range>273-5</page-range>
            <pub-id pub-id-type="pmid">18700440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bielefeldt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levinthal</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis.</article-title>
            <source>Dig Dis Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>687</fpage>
            <page-range>687-693</page-range>
            <pub-id pub-id-type="pmid">29383607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagasawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Torimitsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiba</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yajima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Inokuchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Motomura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kira</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamagishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogra</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iwase</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Ropinirole involved in a fatal case: blood and urinary concentrations.</article-title>
            <source>Forensic Toxicol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>173</fpage>
            <page-range>173-179</page-range>
            <pub-id pub-id-type="pmid">36454487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WYT</given-names>
              </name>
            </person-group>
            <article-title>Orally-dissolving film for sublingual and buccal delivery of ropinirole.</article-title>
            <source>Colloids Surf B Biointerfaces</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>163</volume>
            <fpage>9</fpage>
            <page-range>9-18</page-range>
            <pub-id pub-id-type="pmid">29268211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85736.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijemanne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ondo</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management.</article-title>
            <source>Pract Neurol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>444</fpage>
            <page-range>444-452</page-range>
            <pub-id pub-id-type="pmid">29097554</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
